25 LLC’s Catalyst Pharmaceutical CPRX Stock Holding History

25 LLC’s Portfolio CPRX Stock Details CPRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-43	Closed	-$543	–	151
2023 Q2	$543	Buy	+43	New	+$619	﹤0.01%	462

Other funds holding CPRX

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

25 LLC's CPRX Position: Q3 2023 in Review

25 LLC sold out of Catalyst Pharmaceutical (CPRX) in Q3 2023, closing a stake of 43 shares — an estimated $543 sold.

25 LLC first reported a position in CPRX in Q2 2023 and held it in 1 quarter. The position peaked at $543 in Q2 2023. 255 funds tracked by Wall St. Rank hold CPRX as of Q3 2023.

25 LLC reported no remaining Catalyst Pharmaceutical position as of Q3 2023 after selling out during the quarter.
25 LLC sold 43 Catalyst Pharmaceutical shares in Q3 2023, an estimated $543.
25 LLC first reported a position in Catalyst Pharmaceutical in Q2 2023 and held it in 1 quarter.
25 LLC's Catalyst Pharmaceutical position peaked at $543 in Q2 2023.
255 funds tracked by Wall St. Rank held Catalyst Pharmaceutical as of Q3 2023.

Based on 25 LLC's 13F filing for Q3 2023, filed 18 Oct 2023.